The consumption of sugar-sweetened beverages is driving millions of diabetes and heart disease cases worldwide, with significant regional health inequalities.
Rucaparib camsylate by Pharmaand for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes